These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 876316)

  • 41. Prazosin and congestive heart failure: short- and long-term therapy.
    Rouleau JL; Warnica JW; Burgess JH
    Am J Med; 1981 Jul; 71(1):147-52. PubMed ID: 7246572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
    Awan NA; Lee G; DeMaria AN; Mason DT
    Am Heart J; 1981 May; 101(5):541-7. PubMed ID: 7223594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Importance of neuroendocrine regulators of vascular tone and integral adrenoreceptor interaction during oral vasodilator therapy of severe congestive heart failure with prazosin.
    Awan NA; Beattie JM; Evenson ME; Needham KE; Mason DT
    J Cardiovasc Pharmacol; 1982; 4 Suppl 1():S176-80. PubMed ID: 6175836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effects of acute and chronic vasodilator administration on hemodynamics and catecholamine concentration in chronic left heart failure (author's transl)].
    Klein W; Goebel R
    Z Kardiol; 1980 Feb; 69(2):120-5. PubMed ID: 6779433
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical and polycardiographic evaluation of prazosin in the treatment of chronic congestive heart failure].
    Szmydt W; Kaftańska A; Paradowski S
    Pol Tyg Lek; 1984 Nov; 39(46):1509-12. PubMed ID: 6393093
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of cardiac insufficiency with systemic vasodilator agents].
    García Puig J; Gil Aguado A; Arnalich F; Gaspar G; Anciones B; Vázquez JJ
    Med Clin (Barc); 1980 Nov; 75(9):398-403. PubMed ID: 7464335
    [No Abstract]   [Full Text] [Related]  

  • 47. [Vasodilator treatment of chronic heart failure: a chronic double-blind trial with prazosin and erythrityl tetranitrate].
    Tomov I; Kaloianova A; Terzieva L; Elenkova A; Nikolov G
    Vutr Boles; 1981; 20(6):72-8. PubMed ID: 7039130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prazosin in the treatment of chronic cardiac failure (author's transl)].
    Lanfranchi J; Sachs RN
    Ann Cardiol Angeiol (Paris); 1982; 31(2):133-7. PubMed ID: 7049045
    [No Abstract]   [Full Text] [Related]  

  • 49. Symposium on Congestive Heart Failure. Introduction.
    Conti CR
    Am J Med; 1981 Jul; 71(1):131-4. PubMed ID: 7246570
    [No Abstract]   [Full Text] [Related]  

  • 50. Current indications for vasodilator therapy for left ventricular failure.
    Franciosa JA
    Compr Ther; 1985 Mar; 11(3):39-46. PubMed ID: 2983926
    [No Abstract]   [Full Text] [Related]  

  • 51. [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
    Reifart N; Schmidt-Moritz AD; Nadj M; Kaltenbach M; Bussmann WD
    Z Kardiol; 1985 Apr; 74(4):205-12. PubMed ID: 3923726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
    Mason DT; Awan NA; Joye JA; Lee G; DeMaria AN; Amsterdam EA
    Arch Intern Med; 1980 Dec; 140(12):1577-81. PubMed ID: 6257193
    [No Abstract]   [Full Text] [Related]  

  • 53. [Vasodilator agents in the therapeutic arsenal of cardiac insufficiency].
    Lavitola Pde L; Higa SS
    Rev Paul Med; 1986; 104(3):136-40. PubMed ID: 3563266
    [No Abstract]   [Full Text] [Related]  

  • 54. [Acute and chronic treatment of chronic cardiac insufficiency with nitrates or prazosin respectively].
    Bussmann WD
    Ther Umsch; 1981; 38 Suppl():49-54. PubMed ID: 7339917
    [No Abstract]   [Full Text] [Related]  

  • 55. Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure.
    Franciosa JA
    Prog Cardiovasc Dis; 1982; 24(4):319-30. PubMed ID: 7034048
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure.
    Taylor SH
    Med J Aust; 1980 Jul; 2(SP1):19-35. PubMed ID: 6775178
    [No Abstract]   [Full Text] [Related]  

  • 57. The acute and chronic haemodynamic effects of prazosin in severe congestive cardiac failure.
    Harper RW; Claxton H; Middlebrook K; Anderson S; Pitt A
    Med J Aust; 1980 Jul; 2(SP1):36-8. PubMed ID: 7421721
    [No Abstract]   [Full Text] [Related]  

  • 58. [Sustained and beneficial hemodynamic effects of prazosin in cardiac insufficiency].
    Harrison DC; Feldman RC; Ball RM
    Cardiology; 1980; 66 Suppl 2():162-8. PubMed ID: 6456814
    [No Abstract]   [Full Text] [Related]  

  • 59. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
    Packer M; Meller J; Gorlin R; Herman MV
    Circulation; 1979 Mar; 59(3):531-9. PubMed ID: 761333
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of refractory CHF with prazosin: importance of tolerance and tachyphylaxis.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Acta Med Scand Suppl; 1981; 652():115-24. PubMed ID: 6949458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.